Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tianjin Zhongxin Pharmaceutical Group Acquires Zhongxin Medicine Chain

This article was originally published in PharmAsia News

Executive Summary

Zhongxin Pharmaceuticals recently announced the transfer of its subsidiary Zhongxin Medicine Chain Branch Company to its large shareholder Tianjin Zhongxin Pharmaceutical Group's drug distributor at 49.26 million yuan. As the biggest chain drugstore in Tianjin, Medicine Chain had attracted offers from China's major drug retailers such as Nepstar and Beijing Golden Elephant Chain Drugstore. Observers believe Zhongxin Pharmaceuticals' decision arose from its worries that Medicine Chain will not distribute its products once acquired by a competitor. Zhongxin Pharmaceuticals also said it may buy back Medicine Chain when the latter becomes profitable again. Tianjin is regarded a huge potential market for retail drugs, a fact borne out by the presence of pharmaceutical distributors such as Kaixinren, Laobaixing and Nepstar. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel